SCHEMBL5545570

SCHEMBL5545570

CCOC(=O)c1ncc(Cc2ccc(F)cc2)cc1NCCCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.43
NPSR1 Q6W5P4 5/20 0.43
KMT2A Q03164 5/20 0.43
MEN1 O00255 4/20 0.43
MAPT P10636 4/20 0.43
HPGD P15428 3/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
ALOX12 P18054 1/20 0.43
CCR6 P51684 1/20 0.43
HKDC1 Q2TB90 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
POLB P06746 2/20 0.43
ACHE P22303 3/20 0.42
HTT P42858 3/20 0.42
CASP1 P29466 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546530 0.95 ALDH1A1 (0.45) ALDH1A1NPSR1KMT2AMEN1MAPT
SCHEMBL6062644 0.85 ALDH1A1 (0.41) ALDH1A1NPSR1KMT2AMEN1MAPT
SCHEMBL6062678 0.83 ALDH1A1 (0.42) ALDH1A1NPSR1KMT2AMEN1MAPT
SCHEMBL5543117 0.81 ALDH1A1 (0.45) ALDH1A1MAPTHPGDKDM4ECYP2C19
SCHEMBL5545808 0.81 ALDH1A1 (0.43) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL5540769 0.81 MEN1 (0.37) ALDH1A1NPSR1KMT2AMEN1MAPT
SCHEMBL5540809 0.81 ALDH1A1 (0.43) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL5540936 0.80 KCNQ3 (0.41) ALDH1A1NPSR1KMT2AMEN1MAPT
SCHEMBL5539039 0.80 ALDH1A1 (0.40) ALDH1A1NPSR1KMT2AMEN1MAPT
SCHEMBL4584162 0.79 PTGER4 (0.36) ALDH1A1NPSR1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed
EP-1720856-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-15 EP disclosed
WO-2005077050-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 ALDH1A1 3812/4885NPSR1 4539/4885KMT2A 502/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 ALDH1A1 3073/4885NPSR1 4734/4885KMT2A 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.